[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-bronchopulmonary-aspergillosis-abpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-bronchopulmonary-aspergillosis-abpa":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,73,95,119,152,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100647916","ml-based-abpa-recurrence-prediction-and-clinical-utility-100647916",false,"NCT07714863","ML-Based ABPA Recurrence Prediction and Clinical Utility","Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation","ABPA-ML","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Consistent with the diagnostic consensus criteria for ABPA proposed by the ISHAM-ABPA Working Group.\n3. Patients in stable phase of ABPA: newly diagnosed treatment-naive patients or those with prior ABPA exacerbation who achieved at least 50% improvement in symptoms assessed by Likert scale or visual analogue scale (VAS) following initial therapy, accompanied by marked radiological improvement (≥50% reduction in pulmonary opacities) or a minimum 20% decline in serum total IgE level.\n\nExclusion Criteria:\n\n1. Concurrent malignant tumors or severe organ dysfunction involving the heart, brain, kidney and other vital organs.\n2. Complicated with severe underlying diseases, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease stage 5 (CKD 5), decompensated liver cirrhosis, etc.\n3. Immunocompromised status, such as human immunodeficiency virus (HIV) infection, long-term oral administration of glucocorticoids or immunosuppressive agents.\n4. Pregnant or breastfeeding women.\n5. Patients with missing core clinical data or incomplete medical records.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","1 Year","OBSERVATIONAL","This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis (ABPA) during the stable phase, and further to evaluate the model's practical value in risk stratification and clinical decision-making.\n\nAll patients diagnosed with ABPA according to the ISHAM 2024 criteria will be assigned to either the acute exacerbation group or the non-exacerbation group based on whether they experience an acute exacerbation within 1 year. Enrolled participants will be randomly divided into a training set and an internal validation set. During the feature selection phase, univariate analysis, collinearity diagnostics, feature importance ranking derived from nine machine learning algorithms, and expert consensus are comprehensively applied, ultimately leading to the development of 12 independent machine learning models.\n\nModel performance is assessed using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), sensitivity, specificity, F1-score, calibration curve, and decision curve analysis. In addition, external validation further enhances the credibility of the model. To improve clinical interpretability, the SHAP method is employed to quantify the contribution of each feature, and an interactive nomogram is constructed to facilitate clinical application.\n\nAll participants will be followed up for 12 months, during which regular clinical and laboratory evaluations will be performed.",[26,27,28,29,30],"ABPA","Allergic Bronchopulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis (ABPA)","Acute Exacerbation","Machine Learning",[26,32,30],"Acute exacerbation","RECRUITING","2026-07-14",{"date":36,"type":37},"2026-07-20","ACTUAL",{"date":39,"type":37},"2021-01-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Qianfoshan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":45},"100646535","fungal-status-and-prognosis-in-abpa-100646535","NCT07690345","Fungal Status and Prognosis in ABPA","Clinical Characteristics and Prognostic Outcomes of Allergic Bronchopulmonary Aspergillosis Patients Stratified by Fungal Microbiological Status in Sputum or Bronchoalveolar Lavage Fluid: A Multicenter Bidirectional Cohort Study","ABPAFUNGAL","Inclusion Criteria:\n\n* 1.Adult patients (≥18 years old) diagnosed with allergic bronchopulmonary aspergillosis (ABPA) according to the 2024 International Society for Human and Animal Mycology (ISHAM) diagnostic criteria.\n\n  2.Patients hospitalized during the study period in participating centers with sputum or bronchoalveolar lavage fluid (BALF) collection performed.\n\n  3.At least one mycological test performed on sputum or BALF, including fungal culture, galactomannan (GM) assay, metagenomic next-generation sequencing (mNGS), or targeted next-generation sequencing (tNGS), with clearly interpretable results (positive or negative).\n\n  4.Availability of complete and traceable clinical data, including medical history, imaging, laboratory tests, treatment records, and follow-up information, with no critical missing data.\n\n  5.Willingness to participate in follow-up and signed informed consent (for prospective participants), with good compliance for follow-up.\n\n  6.No systemic antifungal therapy or other interventions that may significantly affect mycological test results within 1 month prior to enrollment.\n\nExclusion Criteria:\n\n* 1.Coexisting pulmonary fungal infections (e.g., invasive pulmonary aspergillosis) or other confirmed non-fungal pulmonary infections.\n\n  2.Presence of other structural lung diseases, such as pulmonary tuberculosis, lung cancer, or lung abscess.\n\n  3.Severe immunodeficiency or other significant allergic pulmonary diseases that may confound the diagnosis of ABPA.\n\n  4.Absence of sputum or BALF samples, or lack of valid mycological test results. 5.Incomplete key clinical data (e.g., total IgE, Aspergillus-specific IgE\u002FIgG, imaging, or pulmonary function data) or inability to complete at least 3 months of follow-up.\n\n  6.Systemic antifungal treatment within 1 month prior to enrollment or participation in another interventional clinical trial.\n\n  7.Contraindications to bronchoscopy\u002FBAL procedures or known severe allergy to relevant reagents used in testing.",{"count":55,"type":21},114,"This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in sputum or bronchoalveolar lavage fluid (BALF).\n\nPatients diagnosed with ABPA according to the ISHAM 2024 criteria will be classified into fungal-positive and fungal-negative groups based on results from fungal culture, galactomannan (GM) testing, and metagenomic next-generation sequencing (mNGS) of sputum or BALF samples.\n\nThe study will compare baseline clinical features, laboratory findings, radiological characteristics, treatment response, and long-term outcomes, including acute exacerbation rate and time to first exacerbation, between the two groups.\n\nAll participants will be followed for up to 12 months with serial clinical and laboratory assessments.",[26,27,28,58],"Colonization",[26,60,61,62,63,64,65],"Aspergillus","bronchiectasis","fungal colonization","BALF","galactomannan","allergic bronchopulmonary mycosis","2026-07-07",{"date":68,"type":37},"2026-07-08",{"date":70,"type":37},"2025-07-01",{"date":41,"type":21},{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":94,"locationsCount":45},"100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551","NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.","80 Years",{"count":82,"type":21},300,"To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[28,30,85,86,87],"Multi-omics","Multicenter Study","Relapse",[27,87,30,86,85],"2026-05-28",{"date":91,"type":37},"2026-06-01",{"date":39,"type":37},{"date":41,"type":21},{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":45},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828","NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":103,"type":21},50,"2 Years","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[26,107,28,108,27,109],"Biologics","Cohort Study","Efficacy and Safety",[111,27,107],"abpa","2026-04-16",{"date":114,"type":37},"2026-04-17",{"date":116,"type":37},"2025-01-31",{"date":41,"type":21},{"name":43,"class":44},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":129,"conditions":130,"keywords":136,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",true,{"count":20,"type":21},"The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[131,132,133,134,135,28],"Airway Inflammation","Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Bronchiectasis","OSAS (Obstructive Sleep Apneas Syndrome)",[137,138,139,140,141],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":144,"type":37},"2026-03-25",{"date":146,"type":37},"2025-08-01",{"date":148,"type":21},"2026-08-01",{"name":150,"class":151},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":45},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":160,"type":21},44,"To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[26,27,28,163,164,165,166],"Airway Clearance","Mucus Plug","Amphotericin B","Bronchoscope",[27,26,165,168,163,169],"bronchoscope","mucus plug","2026-01-15",{"date":172,"type":37},"2026-01-23",{"date":174,"type":37},"2026-01-10",{"date":41,"type":21},{"name":43,"class":44},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":45},"100596044","pathogenesis-and-inflammatory-phenotype-of-allergic-bronchopulmonary-aspergillosis-100596044","NCT07040332","Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n* Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.\n* Meets the diagnostic criteria for fungal-sensitized asthma.\n\nExclusion Criteria:\n\n* Human immunodeficiency virus infection.\n* Malignant tumor.\n* Blood system disease.\n* autoimmune system disease.\n* History of pulmonary tuberculosis.\n* Patients with a history of smoking or still smoking.\n* Invasive pulmonary fungal disease.\n* Contraindications electronic bronchoscopy",{"count":184,"type":21},140,"This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.",[28],{"date":188,"type":37},"2025-07-04",{"date":190,"type":37},"2025-05-10",{"date":192,"type":21},"2029-01-31",{"name":43,"class":44}]